Sunday, November 8, 2026

EUR/JPY Is 4% Down In The Last 21 Sessions

ViaNews Editorial Team

September 13, 2024

EUR/JPY Is 4% Down In The Last 21 Sessions

(VIANEWS) - EUR/JPY (EURJPY) has been up by 4.36% for the last 21 sessions. At 11:06 EST on Friday, 13 September, EUR/JPY (EURJPY) is $155.90.

EUR/JPY's yearly highs and lows, it's 5.486% up from its 52-week low and 11.125% down from its 52-week high.

Volatility

EUR/JPY's last week, last month's, and last quarter's current intraday variation average was a negative 0.44%, a negative 0.14%, and a positive 0.45%, respectively.

EUR/JPY's highest amplitude of average volatility was 0.48% (last week), 0.48% (last month), and 0.45% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/JPY's Forex is considered to be overbought (>=80).

Previous days news about EUR/JPY (EURJPY)

  • Eur/jpy struggles near mid-158.00s, over one-month low amid notable JPY strength. According to FXStreet on Wednesday, 11 September, "The EUR/JPY cross attracts sellers for the second successive day on Wednesday and drops to the 158.20 area, or its lowest level since August 5 during the Asian session. ", "Adding to this, hawkish remarks by Bank of Japan (BoJ) board member Junko Nagakawa provide an additional boost to the JPY and exert downward pressure on the EUR/JPY cross."
  • Eur/jpy trims a part of intraday gains, up a little around 157.00 ahead of ECB decision. According to FXStreet on Thursday, 12 September, "This, along with a generally positive tone around the equity markets, dents demand for the safe-haven JPY and lends support to the EUR/JPY cross.", "Apart from this, ECB President Christine Lagarde's comments at the post-meeting press conference will influence the shared currency and determine the near-term trajectory for the EUR/JPY cross."

More news about EUR/JPY (EURJPY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com